CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. - Wikidata - thesis-toulmin - TriplyDB

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.

http://www.wikidata.org/entity/Q35528462

about

Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosis Current strategies to treat tuberculosis A Blueprint to Address Research Gaps in the Development of Biomarkers for Pediatric Tuberculosis Clinical research and development of tuberculosis diagnostics: moving from silos to synergy Assessment of treatment response in tuberculosis Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis.An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse.Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection Development of a T7 Phage Display Library to Detect Sarcoidosis and Tuberculosis by a Panel of Novel Antigens.Lesion-Specific Immune Response in Granulomas of Patients with Pulmonary Tuberculosis: A Pilot Study RePORT International: Advancing Tuberculosis Biomarker Research Through Global Collaboration.Viewpoint: Challenges and opportunities in tuberculosis research.Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis New drugs to treat tuberculosis.A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation Need for rigor in design, reporting, and interpretation of transcriptomic biomarker studies.Cohort for Tuberculosis Research by the Indo-US Medical Partnership (CTRIUMPH): protocol for a multicentric prospective observational study Circulating biomarkers of pulmonary and extrapulmonary tuberculosis in children.Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure.A metabolic biosignature of early response to anti-tuberculosis treatment.Update in tuberculosis and nontuberculous mycobacterial disease 2011.Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis.Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial.Biomarkers for Treatment Monitoring in Tuberculosis: A New Hope.Novel T7 Phage Display Library Detects Classifiers for Active Mycobacterium Tuberculosis Infection

P2860

Q26824812-2F1E44CA-D831-460D-8147-457EF2433DAB Q28075252-17D7E40D-983D-4C57-A32D-8C54B894F722 Q28082583-0D0F5FB9-66F0-49F0-8615-3247C320B01A Q28383710-CDF24E33-0800-4A09-8EFB-806F79F0F965 Q28384421-5ABBB330-60CA-4BB1-B9F2-B360DB7ACB8E Q28484173-C8463B5E-01AF-4A86-B351-85BEC1AF27E7 Q33638930-368F62D1-9538-4E66-A228-58906A41DADF Q34718431-37F1E0F3-4BBD-42D1-B6AA-07A7A7C08DC9 Q34981779-4451A447-F909-4AF6-A9B5-7B89212A4FA4 Q35666895-853CA1CB-2CAE-4C5B-9FBF-7B554E9A162D Q35680564-11A822DA-17BE-45DD-B542-C1D8FD800558 Q35789291-CFD092AF-303C-4F10-9F8C-47E0F6CBC0F0 Q35907389-648FEA59-5CF1-4767-84AD-425F5282DE3E Q35993510-5D0099DF-02EB-4949-9475-01B2A64556C6 Q36018409-04173146-4897-4559-89A8-FA3B8A0F96FD Q36162053-96EDCEA4-E88C-44F4-9CF9-2C099F480B9B Q36414028-4DDF6502-B336-4D09-A193-245C915D8572 Q36625240-C3A24261-95F1-42A6-920C-8431AC0F5404 Q36826386-71108597-E3CD-4CB9-94FF-2A3F8C338443 Q37434341-932FA897-503B-4DBC-B5F1-40787C16A954 Q37569320-052F7B82-E257-4BDC-94C4-7D25D37E9D51 Q38019488-3EA851D9-D974-436C-9617-227A8113437C Q38221214-F12CD613-AD9C-4388-A612-2F8F972730A1 Q44833599-5EF447F8-2B7F-4545-A201-BB22C4E62949 Q47104871-FFE51454-A1C6-42F0-B5FF-00BC705B9022 Q47565338-A9D04C33-5922-4312-85C6-4FD49820F767 Q56888947-19681690-0DB1-47D2-9706-44E7BB889874

P2860

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.

http://www.wikidata.org/entity/Q35528462

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.

@ast

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.

@en

type

label

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.

@ast

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.

@en

prefLabel

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.

@ast

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.

@en

P1433

Q35528462-87846990-ECD3-45F9-858D-30CFB6CA3E94

P1476

Q35528462-FC575F25-B657-4BEC-81CC-DDEC8B068274

P2093

Q35528462-05D0B4AB-FEB6-45C4-8B6D-AEBC16AF3214

Q35528462-1053C2CA-9A44-4CC3-A55C-E91E0A3F41B9

Q35528462-42398128-EAE0-4179-910A-2D59DACE87E3

Q35528462-4E5F95C6-7047-49B5-9EF3-A37C420396C3

Q35528462-592FFF6E-33F3-4D3C-A8E8-003636DD327F

Q35528462-59AFC852-90B9-4BC7-9C79-8BCCAD0C5AB0

Q35528462-6317BC09-AA69-4C14-8335-A7666FA03BCD

Q35528462-690E6B51-8638-4E5F-8C2C-41BC1BB6992E

Q35528462-707B5EB0-8624-4E35-ACBF-61C919454729

Q35528462-88C0FFC9-5617-41DE-AE04-77268FA27D13

P2860

Q35528462-04717077-3976-4ED4-B0D4-6D772AFB0352

Q35528462-05D77870-00F5-4645-A985-BDFF6E926688

Q35528462-06B4FE49-8B16-4EB1-B03E-D12382BF11CB

Q35528462-07B91E29-B457-455F-BD76-6FA52BC83C0D

Q35528462-0C1C251D-1537-410D-8FBC-F98410690CCE

Q35528462-21D34133-F662-43EF-837E-020CF11CE7F3

Q35528462-32D9E496-E0A9-4656-B341-16ED925DE3C0

Q35528462-42FAB06B-DA9C-45BE-941D-AC0AD1ED020F

Q35528462-4BC581BA-4AD6-4E33-9142-3F9D9728F3A3

Q35528462-4C2172CA-ECD4-4D5E-AE54-AB20BBD45FBD

P304

Q35528462-5DC39A51-2646-4193-BC3D-56E8DE101708

P31

Q35528462-A5E0D792-4152-4FEE-9370-EBA7B302F890

P356

Q35528462-0C22CFB3-4FD9-4C67-A76C-BAAA26AAB329

P407

Q35528462-A2528695-9126-4F5C-A327-60E5CC9A3876

P433

Q35528462-B3708DFE-6596-4FC8-98DA-AB27512A4B93

P478

Q35528462-429B2513-50EC-46D2-9974-D9CFB32A7412

P50

Q35528462-3D0D1197-3DEF-4D49-9FC1-7A8486D7E37B

Q35528462-5CC305AF-9BCE-4FBF-BE71-99E6AF2435E4

Q35528462-67438910-5166-40C7-A353-2B7C06434D1A

Q35528462-CDBE704E-EB58-45BF-8E44-07B3BBD5B7A3

Q35528462-CEF0B34B-4C5D-45A7-9465-7E8A5859CD57

P577

Q35528462-DF669675-E80F-4E48-9CEB-398BF768ED85

P698

Q35528462-A91D6B1B-C518-441B-B039-C303BC4E51F4

P921

Q35528462-1D6A0FE5-EF69-45DC-B6B4-C58A789F1B25

Q35528462-AB944CED-ACE5-4139-A453-5A8544959CEE

Q35528462-BACE92E6-5AA1-4A22-9486-E389320BC921

P932

Q35528462-FA161724-56D0-4157-9226-D7C5E68A108A

P356

RCCM.201105-0827WS

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.

@en

P2093

Constance Benson

http://www.w3.org/2001/XMLSchema#string

Erin Bliven-Sizemore

http://www.w3.org/2001/XMLSchema#string

Janet Andersen

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Lennox

http://www.w3.org/2001/XMLSchema#string

John L Johnson

http://www.w3.org/2001/XMLSchema#string

Jussi Saukkonen

http://www.w3.org/2001/XMLSchema#string

Kathleen D Eisenach

http://www.w3.org/2001/XMLSchema#string

M Elsa Villarino

http://www.w3.org/2001/XMLSchema#string

Mamodikoe Makhene

http://www.w3.org/2001/XMLSchema#string

Marc Weiner

http://www.w3.org/2001/XMLSchema#string

P2860

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa.

Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop.

Recurrent tuberculosis in the United States and Canada: relapse or reinfection?

Biomarkers of treatment response in clinical trials of novel antituberculosis agents.

Banking of biological fluids for studies of disease-associated protein biomarkers

Biomarkers for TB treatment response: challenges and future strategies.

Using animal models to develop new treatments for tuberculosis.

P304

972-979

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.201105-0827WS

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

184

http://www.w3.org/2001/XMLSchema#string

P50

National Institutes of Health

Centers for Disease Control and Prevention

Anne F. Luetkemeyer

Susan Swindells

P577

2011-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21737585

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

3208659

http://www.w3.org/2001/XMLSchema#string